Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Find studies

Showing 126–150 of 475 studies in Caregiving · free to read (page 6 of 19) · 31,380 in the whole library · How the 0–100 score works

Download bibliography of these 475 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

What “Caregiving” covers

Caregiving — Research on the people doing the caring: their health, their workload, and what support actually helps.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

2014 Alzheimer's disease facts and figures

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2014-03-01

This report discusses the public health impact of Alzheimer's disease (AD), including incidence and prevalence, mortality rates, costs of care, and overall effect on caregivers and society. 2 key findings →

Participants: 200,000 Evidence: low

This study sought to determine the prevalence and impact of pain in a nationally representative sample of older adults in the United States. 3 key findings →

Participants: 7,601 Evidence: low

Blood-brain barrier opening with focused ultrasound in Parkinson's disease dementia

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Nature communications 2021-02-03

MR-guided focused ultrasound (MRgFUS), in combination with intravenous microbubble administration, has been applied for focal temporary BBB opening in patients with neurodegenerative disorders and brain tumors. 4 key findings →

Evidence: high

The evidence is not conclusive as to whether some symptoms are more important than others. 3 key findings →

Design: systematic review Evidence: high

Association of Higher Cortical Amyloid Burden With Loneliness in Cognitively Normal Older Adults

✓ Peer-reviewed alzhub usefulness score 60 out of 100. JAMA psychiatry 2016-12-01

Loneliness is a perceived state of social and emotional isolation that has been associated with cognitive and functional decline and an increased risk of incident AD dementia. 5 key findings →

Design: cross-sectional Participants: 25 Evidence: low

Delirium in the emergency department: an independent predictor of death within 6 months

✓ Peer-reviewed alzhub usefulness score 60 out of 100. Annals of emergency medicine 2010-04-03

Study objective Delirium's adverse effect on long-term mortality in older hospitalized patients is well documented, whereas its effect in older emergency department (ED) patients remains unclear. 4 key findings →

Design: cohort study Participants: 628 Evidence: moderate

Vascular endothelial growth factor was associated with baseline hippocampal volume (t277 = 2.62; P = .009), longitudinal hippocampal atrophy (t858 = 2.48; P = .01), and longitudinal decline in memory (t1629 = 4.09; P Conclusions and relevance Elevated cerebrospinal fluid VEGF was associated with more optimal brain aging in vivo. 4 key findings →

Design: longitudinal study Participants: 90 Evidence: moderate

Anticholinergic medication burden in schizophrenia is substantial, common, conferred by multiple medication classes, and associated with cognitive impairments across all cognitive domains. 4 key findings →

Design: cross-sectional Participants: 1,120 Evidence: low

The intervention revealed no substantial between-group differences in caregiver burden (β=-3.80, 95% CI -11.25 to 3.65, P=.32), quality of life (β=-1.55, 95% CI -6.59 to 3.49, P=.55), or social support (β=0.85, 95% CI -2.86 to 4.56, P=.65). 5 key findings →

Design: randomized controlled trial Participants: 60 Evidence: high

Attendance was good (82.8% attended ≥4/6 sessions). 5 key findings →

Design: randomized controlled trial Evidence: high

Improving digital technology for caregivers requires studies with larger populations and longitudinal outcomes. 1 key finding →

Design: RCT Participants: 240 Evidence: early

One hundred sixteen participants consented and 93 (46 waitlist control, 47 intervention) were included in the analyses. 3 key findings →

Design: RCT Participants: 93 Evidence: null result

Cholinesterase inhibitors benefit patients with AD (Standard), although the average benefit appears small; vitamin E likely delays the time to clinical worsening (Guideline); selegiline, other antioxidants, anti-inflammatories, and estrogen require further study. 1 key finding →

Evidence: low

Coping style may be more associated with anxiety than depression while other covariates (burden and poor physical health) are similar to those for caregiver depression. 5 key findings →

Design: systematic review Evidence: high

As the physiological impact of chronic stress is difficult to study in humans, naturalistic stressors are invaluable sources of information in this area. 2 key findings →

Evidence: low

Such complex needs require an integrated response from general health professionals and multidisciplinary dementia specialists. 1 key finding →

Design: cross-sectional Participants: 291,169 Evidence: low

Longitudinal analysis revealed progressive and widespread changes in the grey matter, notably including the basal ganglia. 4 key findings →

Design: cross-sectional Participants: 36 Evidence: moderate

Increased BPSD was reported in 59.6% of patients as worsening of preexisting symptoms (51.9%) or as new onset (26%), and requested drug modifications in 27.6% of these cases. 4 key findings →

Participants: 4,913 Evidence: low

Despite evidence of ethnic differences in family caregivers' experiences, the extent to which caregiver interventions are culturally tailored to address these differences is unknown. 1 key finding →

Design: systematic review Evidence: high

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomized / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multicenter collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 31,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,380 records, built mostly from automated pulls of Europe PMC (65.6% of the library) and OpenAlex (16.2%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,048 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events